BioScrip to Present at the Bank of America Merrill Lynch 2018 Leveraged Finance Conference
November 20 2018 - 9:00AM
BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the
largest independent national provider of infusion and home care
management solutions, today announced that Daniel E. Greenleaf,
President and Chief Executive Officer, and Stephen M. Deitsch,
Senior Vice President, Chief Financial Officer and Treasurer, will
present at the Bank of America Merrill Lynch 2018 Leveraged Finance
Conference on Wednesday, December 5, 2018 at 10:10 a.m. ET at the
Boca Raton Resort & Club in Boca Raton, Florida.
A live webcast of the presentation and copies of materials
presented can be accessed via the Company’s Investor Relations
website at https://investors.bioscrip.com/ or through the following
link:
https://www.veracast.com/webcasts/baml/levfin2018/id64205622087.cfm.
About BioScrip, Inc.
BioScrip, Inc. is the largest independent
national provider of infusion and home care management solutions,
with approximately 2,100 teammates and nearly 70 service locations
across the U.S. BioScrip partners with physicians, hospital
systems, payors, pharmaceutical manufacturers and skilled nursing
facilities to provide patients access to post-acute care services.
BioScrip operates with a commitment to bring customer-focused
pharmacy and related healthcare infusion therapy services into the
home or alternate-site setting. By collaborating with the full
spectrum of healthcare professionals and the patient, BioScrip
provides cost-effective care that is driven by clinical excellence,
customer service, and values that promote positive outcomes and an
enhanced quality of life for those it serves.
Investor Contacts:
Stephen
Deitsch |
Kalle Ahl, CFA |
Chief Financial Officer
& Treasurer |
The Equity Group |
T: (720)
697-5200 |
T: (212)
836-9614 |
stephen.deitsch@bioscrip.com |
kahl@equityny.com |
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioPlus Acquisition (NASDAQ:BIOS)
Historical Stock Chart
From Apr 2023 to Apr 2024